Adderall XR – Sudden Death, Convulsions added to label


As reported by Wayne Kondro,1 Health Canada’s February 2005 decision to withdraw Adderall XR (a mixture of 4 amphetamine salts marketed by Shire Biochem for the treatment of attention deficit hyperactivity disorders [ADHD]) was reversed in August by a 3-member New Drug Committee. Stronger labelling has been recommended, and sudden death, myocardial infarction, cerebrovascular accident and convulsion will be added to the list of adverse drug reactions (instead).

This situation raises a number of disturbing questions. Read more…

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.